首页> 外文期刊>International archives of allergy and immunology >In search of a vaccine for mouse allergy: Significant reduction of mus m 1 allergenicity by structure-guided single-point mutations
【24h】

In search of a vaccine for mouse allergy: Significant reduction of mus m 1 allergenicity by structure-guided single-point mutations

机译:寻找针对小鼠过敏的疫苗:通过结构引导的单点突变显着降低mus m 1致敏性

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Mouse urinary proteins are relevant allergens from mice urine. We used the recombinant protein Mus m 1 as an allergen model to identify if, by altering Mus m 1 architecture via single-point mutations, we could effectively modify its allergenicity. Methods: Based on structural considerations, we synthesized two single-point mutants, Mus m 1-Y120A and Mus m 1-Y120F, which were expected to harbor large structural alterations. Circular dichroism and fluorescence analysis showed significant conformational rearrangements of the aromatic side chains in the internal cavity of Mus m 1-Y120A when compared to Mus m 1-Y120F and Mus m 1. Evaluation of the allergenic potential of the recombinant molecules was performed in vitro with both immunochemical approaches and assays based on the measurement of basophil degranulation. Moreover, to assess the integrity of the T cell epitopes and as an in vitro measure of immuno- genicity, we tested the reactivity of T lymphocytes from subjects allergic to mouse urine against proteins and synthetic peptides encompassing the immunodominant linear epitope containing the mutation. Results: We found that the selected point mutation was able to modulate the protein allergenicity, and to severely impair the recognition of Mus m 1 by IgE, while T cell reactivity was fully maintained. Conclusions: In silico predicted, minimum selected structural modifications allowed to design one protein with reduced allergenicity and preserved immunogenicity. Structurally guided mutations can direct the design of proteins with reduced allergenicity which can be used as vaccines for a safer and more effective immunotherapy of allergic disorders.
机译:背景:小鼠尿蛋白是来自小鼠尿液的相关过敏原。我们使用重组蛋白Mus m 1作为变应原模型,通过通过单点突变改变Mus m 1结构来确定我们是否可以有效地改变其变应原性。方法:基于结构上的考虑,我们合成了两个单点突变体,Mus m 1-Y120A和Mus m 1-Y120F,它们有望具有较大的结构改变。圆二色性和荧光分析显示,与Mus m 1-Y120F和Mus m 1相比,Mus m 1-Y120A内腔中的芳香族侧链具有显着的构象重排。在体外评估了重组分子的致敏潜力结合免疫化学方法和基于嗜碱性粒细胞脱粒测量的分析方法。此外,为了评估T细胞表位的完整性,并作为体外免疫原性的方法,我们测试了对小鼠尿液过敏的受试者的T淋巴细胞对蛋白质和合成肽的反应性,这些蛋白质和合成肽包含具有突变的免疫显性线性表位。结果:我们发现选择的点突变能够调节蛋白质的致敏性,并严重损害IgE对Mus m 1的识别,同时完全维持T细胞反应性。结论:在计算机模拟中,选择的最少结构修饰可以设计出一种具有降低的变应原性和保留的免疫原性的蛋白质。结构上指导的突变可以指导具有降低的致敏性的蛋白质的设计,其可用作疫苗用于更安全,更有效的过敏性疾病免疫治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号